BridgeBio Says Interim Analysis of BBP-418 Showed Individuals Reaching Normal Levels on Limb-Girdle Muscular Dystrophy Markers
MT newswire2026/10/05 12:4108:41 AM EDT, 10/05/2026 (MT Newswires) -- BridgeBio Pharma (BBIO) said Monday that new exploratory cardiac data from the 12-month interim analysis of Fortify phase 3 study of oral BBP-418 showed individuals with limb-girdle muscular dystrophy type 2I/R9 reaching normal or near-normal levels on disease markers. Data demonstrated that all participants treated with BBP-418 returned to the normal range for HS troponin l, a blood test used to detect injury to heart muscle, by month 12, compared with 40% for the placebo arm, the company said. Additionally, 54% of participants treated with BBP-418 had stable or improved left ventricular ejection fraction, a measure of how much blood is being pushed out by the heart's main chamber with each beat, at month 12 versus 25% for those on placebo, BridgeBio Pharma said. BBP-418 is currently under the US Food and Drug Administration's priority review with a Prescription Drug User Fee Act target action date of Nov. 27, according to a statement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
